Fatty liver (MASLD/MASH)
MASLD (metabolic dysfunction-associated steatotic liver disease, formerly known as NAFLD) is a build-up of fat in the liver linked to insulin resistance; MASH (formerly NASH) is a more advanced, inflamed form that can progress to scarring (fibrosis) and, less often, cirrhosis. It's extremely common — affecting roughly 4 in 10 adults in India, and more than half of adults with diabetes — and is best understood as a liver-specific marker of broader metabolic risk, assessed and managed alongside your diabetes, weight, and lipid care rather than as an isolated liver problem.
Your MASLD/MASH assessment pathway
Identifying Risk
Reviewing your diabetes, weight, and lipid profile for the cardiometabolic risk factors that go with MASLD.
Confirming Steatosis
Blood tests and a liver ultrasound to check for fat in the liver.
Non-Invasive Fibrosis Risk Scoring (FIB-4)
A blood-test-based calculation used as the first step to estimate fibrosis risk.
Elastography Where Indicated
A follow-up scan (such as FibroScan) to further clarify risk when FIB-4 is indeterminate or you're in a high-risk group.
A Personalized Management Plan
Addressing the metabolic drivers, with medicines considered where appropriate.
Ongoing Monitoring
Risk and severity are reassessed over time, not judged from a single test.
Symptoms
- Usually no symptoms in early stages — often found incidentally on imaging or blood tests
- Fatigue or discomfort in the upper right abdomen in some cases
- Signs of advanced liver disease in later stages, which need prompt evaluation
Causes & risk factors
- Insulin resistance and type 2 diabetes
- Obesity, particularly abdominal obesity
- Dyslipidemia
- MetALD — a related category for MASLD alongside alcohol intake above defined thresholds
MASLD is very common in India — recent cohort data estimates roughly 38–39% of Indian adults are affected overall, rising to about 57% among adults with diabetes. Prevalence is markedly higher in urban areas (around 47%) than rural areas (around 19%), reflecting the role of lifestyle and metabolic risk factors.
Why MASLD matters beyond the liver
MASLD is best understood as a signal of broader metabolic risk, not a problem confined to the liver — which is why it's assessed alongside your diabetes, weight, and lipid profile rather than in isolation.
The liver itself
Fat accumulation can progress to inflammation (MASH), scarring (fibrosis), and rarely cirrhosis if unaddressed
Metabolic risk
MASLD shares its underlying drivers — insulin resistance, obesity, dyslipidemia — with diabetes and metabolic syndrome
Cardiovascular risk
People with MASLD carry higher cardiovascular risk overall, independent of liver severity
From MASLD to MASH to fibrosis: understanding the spectrum
MASLD isn't one fixed condition — it's a spectrum, and where you sit on it shapes both monitoring and treatment.
| Stage | What it means | Why it matters |
|---|---|---|
| MASLD (steatosis) | Fat in the liver without significant inflammation | The starting point — often reversible with metabolic risk factor management |
| MASH | Fat plus liver inflammation and cell injury | The stage most associated with progression if unaddressed |
| Fibrosis | Scarring of liver tissue, graded F0 (none) to F4 (cirrhosis) | The key severity marker — F2–F3 fibrosis is the current treatment target for approved medicines |
| Cirrhosis | Advanced, extensive scarring (F4) | Carries risk of liver-related complications and needs specialist, closely monitored care |
Assessing your fibrosis risk: FIB-4 and elastography
Current guidelines recommend a staged approach — a simple blood-based score first, followed by imaging only where it's actually needed, rather than an invasive test for everyone.
- FIB-4 is calculated from routine blood results (age, liver enzymes, and platelet count) — no extra test is needed to calculate it
- Elastography is a non-invasive scan that estimates liver stiffness as a proxy for fibrosis, avoiding a biopsy for most patients
| FIB-4 result | What it suggests | What happens next |
|---|---|---|
| Below 1.3 (or below 2.0 if you're over 65) | Advanced fibrosis is unlikely | Continue routine metabolic risk management and periodic reassessment |
| Indeterminate range | Fibrosis risk isn't clear from this test alone | Further testing with elastography (such as FibroScan) or another non-invasive test |
| Above 2.67 | Advanced fibrosis is more likely | Closer evaluation, often with elastography and specialist input |
Treatment: what actually helps
There's no single medicine that reverses fatty liver for everyone — treatment centers on the metabolic drivers, with a growing but still selective set of liver-specific options.
- Weight loss remains the most consistently effective measure — even a 7–10% reduction in body weight is associated with meaningful improvement in liver fat and, at the higher end, inflammation
- GLP-1 therapy (semaglutide): a phase 3 trial (ESSENCE, published in the New England Journal of Medicine) found that at 72 weeks, semaglutide led to MASH resolution without worsening fibrosis in 62.9% of patients (vs. 34.3% on placebo), and fibrosis improvement without worsening MASH in 36.8% (vs. 22.4% on placebo) — see our GLP-1 therapy page for more detail
- Pioglitazone and vitamin E have an established evidence base for MASH in appropriately selected, non-cirrhotic patients, individualized by your care team
- Managing diabetes, blood pressure, and lipids to their own targets remains part of the plan regardless of which liver-specific option, if any, is used
Resmetirom — a note on availability
- Resmetirom is the first medicine specifically approved (by the US FDA, in 2024) for MASH with moderate-to-advanced fibrosis (stages F2–F3), used alongside diet and exercise
- It is not officially marketed in India as of this review — access, where pursued, generally involves a named-patient import process rather than routine local prescribing
- This is noted here for awareness, not as a recommendation — its role for you, if any, would be discussed individually
Monitoring and follow-up
MASLD/MASH is followed over time rather than assessed once — your fibrosis risk, weight, glucose, and lipid profile are reviewed together at follow-up, with repeat non-invasive testing guided by your initial risk category and how your metabolic risk factors are responding to treatment.
How it’s diagnosed
Diagnosis typically starts with blood tests and liver ultrasound to confirm fat in the liver, followed by a non-invasive fibrosis risk score (FIB-4) and, where indicated, elastography to assess severity — coordinated through partner facilities for imaging.
How it’s treated
Management centers on treating the underlying metabolic drivers — weight, glucose, and lipid management — since only a small number of medicines are approved specifically for liver disease itself; some diabetes and weight-management therapies (including GLP-1 medicines) have shown direct liver benefits in clinical trials.
When to seek care
- Yellowing of the skin or eyes (jaundice)
- Significant abdominal swelling
- Unexplained, ongoing abdominal pain
- Vomiting blood, or passing black or tarry stools
- New confusion, drowsiness, or a marked change in behavior
FAQ
Why did the name change from NAFLD/NASH to MASLD/MASH?
A 2023 multi-society consensus renamed these conditions to reflect their metabolic basis more precisely. The conditions themselves are the same; MASLD/MASH is simply the current terminology.
What's the difference between MASLD and MASH?
MASLD is fat in the liver without significant inflammation. MASH is a more advanced stage that includes liver inflammation and cell injury, and is the stage most associated with progression to fibrosis if unaddressed.
How common is MASLD in India?
Very common — recent cohort data estimates roughly 38–39% of Indian adults are affected, rising to about 57% among adults with diabetes, and notably higher in urban than rural areas.
Why does diabetes increase my risk of fatty liver?
MASLD and type 2 diabetes share the same underlying driver — insulin resistance — which is why the two conditions occur together so often and why liver health is checked as part of diabetes care.
Is fatty liver dangerous? Can it progress to cirrhosis?
It can, in a minority of patients — MASLD can progress through MASH to fibrosis and, less often, cirrhosis. This is why fibrosis risk is assessed rather than assumed, so care can be intensified for those who need it.
How is MASLD diagnosed?
Typically with blood tests and a liver ultrasound to confirm fat in the liver, followed by a fibrosis risk score (FIB-4) and, where indicated, elastography to assess severity.
What is FIB-4?
FIB-4 is a fibrosis risk score calculated from your age, liver enzyme levels, and platelet count — all from routine blood results — used as a first-step, no-extra-test way to estimate whether advanced fibrosis is likely.
What is elastography or FibroScan?
It's a non-invasive scan that estimates liver stiffness as a proxy for fibrosis, used as a second step when FIB-4 results are indeterminate or you're in a higher-risk group — it helps avoid a liver biopsy for most patients.
Can fatty liver be reversed?
Often, yes, particularly at the MASLD (steatosis) stage — sustained weight loss and metabolic risk factor management can meaningfully reduce liver fat and, at higher levels of weight loss, improve inflammation and fibrosis for some patients.
How much weight loss actually helps?
A 7–10% reduction in body weight is associated with meaningful improvement in liver fat and inflammation for many patients — larger reductions are linked to greater improvement, individualized to your starting point and overall plan.
Can GLP-1 medicines treat MASH?
Evidence is genuinely encouraging: a phase 3 trial (ESSENCE, published in 2025) found that semaglutide led to MASH resolution without worsening fibrosis in 62.9% of patients at 72 weeks, versus 34.3% on placebo. In August 2025 the US FDA gave semaglutide accelerated approval for MASH with moderate-to-advanced fibrosis (F2–F3). See our GLP-1 therapy page for more on this treatment option specifically.
Is there a medicine approved specifically for MASH?
Resmetirom was approved by the US FDA in 2024 for MASH with moderate-to-advanced fibrosis, alongside diet and exercise. It is not officially marketed in India as of this review, so its role, if any, is discussed individually.
Does alcohol matter if I have MASLD?
Yes — MetALD is a related category for people with MASLD who also drink alcohol above defined thresholds, since alcohol can compound liver injury. This is discussed as part of your assessment.
Will I need a liver biopsy?
Most patients don't — the current staged approach (FIB-4, then elastography where needed) avoids biopsy for most people, reserving it for situations where non-invasive tests don't give a clear enough picture.
How often should I be monitored?
This depends on your initial fibrosis risk category and how your metabolic risk factors respond to treatment, rather than a fixed schedule for everyone — your care team will advise on timing suited to you.
Is fatty liver linked to heart disease?
Yes — people with MASLD carry higher cardiovascular risk overall, independent of how severe the liver disease itself is, which is one reason it's managed as part of your broader metabolic care rather than as an isolated liver issue.
Medical disclaimer: Content on this page is for general education and is not a substitute for individualized medical advice, diagnosis, or treatment. Outcomes vary between patients. Boston Diabetes Center is outpatient / day-care specialty centre with an on-site diagnostic lab and pharmacy — no inpatient beds; imaging and inpatient care are coordinated through partner facilities.